Acne
Mark Lebwohl, M.D.
Mt. Sinai School of
Medicine
Definition/Key
Clinical Features
Differential
Diagnosis
Best
Tests
Best
Therapy
Best
References
Definition/Key
Clinical Features
- Characteristic skin lesions
- Open and closed comedones
- Erythematous papules
- Pustules
- Nodules
- Cysts
- Scars
- Most commonly affects face but can
involve back and chest
- Earlier onset and increased severity
in males
- Premenstrual flares common in
females
Major Forms
Comedonal Acne
- Comedones
- Predominance of open (blackheads) and closed
(whiteheads) comedones
Inflammatory Acne
- Erythematous papules (3–10 mm)
- Develop into pustules or resolve into fading
erythematous macule
- May cause postinflammatory hyperpigmentation
- Pustules
- Superficial, dry in a few days
- Nodules (≥ 1 cm)
- Firm, erythematous, tender nodules becoming fluctuant
or forming cysts
- Fluctuant sinuses result in postinflammatory
pigmentary changes and scarring
Clinical Variants
- Acne conglobata
- Severe form with confluent large cysts, abscesses, and
draining sinus tracts
- Acne cosmetica
- Low-grade form resulting from use of greasy, occlusive
cosmetics and lotions
- Acne excoriée
- Large ulcers and erosions caused by picking of minor
lesions
- Acne mechanica
- From repeated trauma and rubbing (e.g., wearing sports
helmets, shoulder pads, or bras)
- Pomade acne
- Caused by thick oils in hair
- Neonatal and infantile acne
- Erythematous papules and pustules lasting 2–6 mo after
birth
- May signal severe acne later in life
Differential
Diagnosis
- Folliculitis
- Milia
- Perioral dermatitis
- Chloracne
- Hidradenitis suppurativa
- Favre-Racouchot disease
- Rosacea
Best
Tests
- Diagnose by clinical features
Best
Therapy
- Depends on acne type and severity
Topical Therapies
Comedonal Acne
- Topical retinoids to unplug follicles and allow topical
antibiotic and benzoyl peroxide penetration
Inflammatory Acne
- Treatment alternatives (by effectiveness)
- Retinoids and benzoyl peroxide most effective
- Topical antibiotics less effective but better
tolerated
- Can be used in combination with benzoyl peroxide
(clindamycin 1% and benzoyl peroxide 5%)
- Common regimen: antibiotic–benzoyl peroxide in
morning and topical retinoid in evening
- Azelaic acid
- Can be used in combination with topical retinoids,
benzoyl peroxide, or topical antibiotics
- Sulfur-resorcinol lotion
- Effective drying and peeling agent for treating
individual lesions
Topical Drugs for Acne
Retinoids
- Most effective
- Adverse effects
- Dryness
- Irritation
- Photosensitivity
- Adapalene
- Dose: 0.1% gel q.d.
- Cost/mo: 45 g/$95
- Tazarotene
- Dose: 0.05% or 0.1% gel q.d.
- Cost/mo: 30 g/$99
- Tretinoin
- Dose: 0.01%–0.05% preparations q.d.
- Cost/mo: 20 g/$45
Benzoyl Peroxide
- Most effective
- Adverse effects
- Dose: 2.5%–10% preparations b.i.d.
- Cost/mo: 45 g/$14
Antibiotics
- Clindamycin
- Adverse effects
- Dose: 1% preparation b.i.d.
- Cost/mo: 30 g/$19
- Erythromycin
- Adverse effects
- Dose: 2% preparation b.i.d.
- Cost/mo: 30 g/$18
- Erythromycin–benzoyl peroxide
- Adverse effects
- Dryness
- Irritation
- Contact dermatitis
- Dose: 3% erythromycin, 5% benzoyl peroxide gel
b.i.d.
- Cost/mo: 46.6 g/$92
- Sodium sulfacetamide–sulfur
- Adverse effects
- Dryness
- Irritation
- Contact dermatitis
- Dose: 10% sodium sulfacetamide, 5% sulfur lotion
b.i.d.
- Cost/mo: 30 g/$22
Azelaic Acid
- Adverse effects
- Dose: 20% cream b.i.d.
- Cost/mo: 30 g /$57
Sulfur and Resorcinol
- Adverse effects
- Dryness
- Peeling
- Contact dermatitis
- Dose: 2% resorcinol, 8% sulfur preparation q.d. or
b.i.d.
- Cost/mo: 28 g/$6
Salicylic Acid
- Adverse effects
- Dose: 0.5%–2% preparations q.d. or b.i.d.
- Cost/mo: 148 g/$6
Systemic Therapies for Nodulocystic Acne or Inflammatory
Acne Unresponsive to Topical Therapy
Antibiotics: First-Line Therapy
- Long-term use of antibiotics for the treatment of acne
may be associated with increased risk of breast cancer
- Doxycycline
- Adverse effects
- Photosensitivity
- GI symptoms
- Candidiasis
- Dose: 50–100 mg p.o., b.i.d.
- Cost/mo: $22
- Erythromycin
- Adverse effects
- Dose: 250–500 mg p.o., b.i.d.
- Cost/mo: $17
- Minocycline
- Adverse effects
- GI symptoms
- Candidiasis
- Vertigo
- Lupuslike syndrome (rare)
- Hepatitis (rare)
- Dose: 50 mg p.o., q.d., to 100 mg p.o., q.i.d.
- Cost/mo: $77
- Tetracycline
- Adverse effects
- Photosensitivity
- GI symptoms
- Candidiasis
- Dose: 250 mg p.o., q.d., to 500 mg p.o., q.i.d.;
b.i.d. preferred
- Cost/mo: $8
- Trimethoprim-sulfamethoxazole
- Adverse effects
- Bone marrow suppression
- Drug eruption
- Dose: 160 mg trimethoprim, 800 mg sulfamethoxazole
b.i.d.
- Cost/mo: $18
- Isotretinoin
- Most effective agent; long-lasting remissions or
cures; not used as first-line therapy because of serious potential adverse
effects (teratogenicity, hyperlipidemia, cheilitis, alopecia, pyogenic
granulomas, dry eyes, epistaxis, pseudotumor cerebri [rare]); limit
treatment to 4–6 mo or refer
- Central registry for physicians, pharmacists, and
patients being established to prevent use during pregnancy
- Dose: 0.5–1 mg/kg/day in 2 divided doses, to a
cumulative dose of 120–150 mg/kg
Hormone Therapy
- Norgestimate–ethinyl estradiol
- For women only; alternative to antibiotics and
isotretinoin
- Adverse effects
- Thromboembolic disorders
- Fluid retention
- Hypertension
- Breakthrough bleeding
- Breast swelling and tenderness
- Dose: 0.18 mg norgestimate, 0.035 mg ethinyl estradiol
p.o., q.d., for 21 days; repeat q. 4 wk
- Cost/mo: $30
Other Therapies
- Consider referral for the following:
- Photodynamic therapy
- Specialized abrasion therapy
- Injections
- Surgery
Therapy for Rosacea
- Avoid triggers such as alcohol, hot or spicy foods, or
heat
- Sunscreens
- Laser therapy for telangiectasia
- Topical and oral antibiotics for papules and pustules,
as for acne, but benzoyl peroxide less commonly used than for acne
- Azelaic acid for erythema
Best References
Babilas P, et al: Photodermatol Photoimmunol Photomed
21:142, 2005
Mendelsohn AB, et al: Pharmacoepidemiol Drug Saf, May 12,
2005
Tan J: J Cutan Med Surg, Mar 31, 2005
Tan J, et al: Expert Opin Pharmacother 6:409,
2005
The author has received grants from Allergan Inc.,
Connetics Corp., Medicis, and Ortho-McNeil Pharmaceutical, Inc.
October
2005
© 2008 BC Decker Inc. All rights reserved. [an error occurred while processing this directive]